Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats.

The Journal of Pharmacology and Experimental Therapeutics
Maria SchermaSteven R Goldberg

Abstract

Emerging evidence suggests that the rewarding, abuse-related effects of nicotine are modulated by the endocannabinoid system of the brain. For example, pharmacological blockade or genetic deletion of cannabinoid CB(1) receptors can reduce or eliminate many abuse-related behavioral and neurochemical effects of nicotine. Furthermore, doses of Delta(9)-tetrahydrocannabinol and nicotine that are ineffective when given alone can induce conditioned place preference when given together. These previous studies have used systemically administered CB(1) receptor agonists and antagonists and gene deletion techniques, which affect cannabinoid CB(1) receptors throughout the brain. A more functionally selective way to alter endocannabinoid activity is to inhibit fatty acid amide hydrolase (FAAH), thereby magnifying and prolonging the effects of the endocannabinoid anandamide only when and where it is synthesized and released on demand. Here, we combined behavioral and neurochemical approaches to evaluate whether the FAAH inhibitor URB597 (cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester) could alter the abuse-related effects of nicotine in rats. We found that URB597, at a dose (0.3 mg/kg) that had no behavioral effects by itself, prevented d...Continue Reading

References

Jan 1, 1989·Psychopharmacology·W A Corrigall, K M Coen
Sep 23, 1987·European Journal of Pharmacology·G MereuT C Westfall
Apr 1, 1997·Psychopharmacology·Y ShahamW A Corrigall
Dec 2, 1998·Behavioural Pharmacology·C CastellanoS Puglisi-Allegra
Jan 5, 2002·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·M R PicciottoJ P Changeux
Jan 30, 2002·British Journal of Pharmacology·Emmanuel ValjentRafael Maldonado
Nov 19, 2002·Journal of Neurobiology·Huibert D Mansvelder, Daniel S McGehee
Dec 4, 2002·Nature Medicine·Satish KathuriaDaniele Piomelli
May 20, 2003·The European Journal of Neuroscience·L FattoreW Fratta
May 23, 2003·The Journal of Biological Chemistry·Gerard P Ahern
Oct 4, 2003·Science·Giovanni MarsicanoBeat Lutz
Dec 20, 2003·Current Drug Targets. CNS and Neurological Disorders·Claudio CastellanoMarco Costanzi
Jan 13, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Miriam MelisGian Luigi Gessa
Oct 16, 2004·Neuroreport·Bernard Le Foll, Steven R Goldberg
Mar 15, 2005·Psychopharmacology·Bernard Le Foll, Steven R Goldberg
Jun 1, 2005·Pharmacology, Biochemistry, and Behavior·Anna CastañéRafael Maldonado
Jun 30, 2005·Psychopharmacology·Benoît ForgetMarie-Hélène Thiébot
Oct 6, 2005·Psychopharmacology·Bernard Le Foll, Steven R Goldberg
Dec 15, 2005·Proceedings of the National Academy of Sciences of the United States of America·G GobbiD Piomelli
May 17, 2006·The Journal of Pharmacology and Experimental Therapeutics·Giuseppe AstaritaDaniele Piomelli
Jul 13, 2006·CNS Drug Reviews·Daniele PiomelliDavid Putman
Mar 14, 2007·Current Opinion in Lipidology·Vincenzo Di Marzo, Stefania Petrosino
Oct 2, 2007·British Journal of Pharmacology·Y SunA J Bennett
May 3, 2008·The Journal of Pharmacology and Experimental Therapeutics·Lisa L MerrittM Imad Damaj

❮ Previous
Next ❯

Citations

Mar 21, 2009·Psychopharmacology·Bernard Le FollSteven R Goldberg
Dec 17, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Francesca M FilbeyKent E Hutchison
Nov 22, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Matthew W BuczynskiLoren H Parsons
Mar 29, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Leigh V PanlilioSteven R Goldberg
Jan 15, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Leigh V PanlilioSteven R Goldberg
Oct 31, 2012·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Miriam Melis, Marco Pistis
Dec 19, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Miriam MelisMarco Pistis
May 13, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Zuzana JustinováSteven R Goldberg
Oct 19, 2013·The Proceedings of the Nutrition Society·Roger G Pertwee
May 21, 2013·Addictive Behaviors·Celia J A MorganSunjeev K Kamboj
Nov 20, 2013·Psychopharmacology·Cristiane Ribeiro De CarvalhoReinaldo Naoto Takahashi
Jul 19, 2012·Annual Review of Psychology·Raphael Mechoulam, Linda A Parker
Apr 8, 2014·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Miriam Melis, Marco Pistis
Feb 3, 2009·The AAPS Journal·Joel E SchlosburgAron H Lichtman
Jun 15, 2010·Expert Opinion on Drug Discovery·Kay AhnBenjamin F Cravatt
Jun 19, 2012·Life Sciences·Pretal P MuldoonM Imad Damaj
Jul 30, 2011·Pharmacology & Therapeutics·Antonia Serrano, Loren H Parsons
Jun 15, 2011·Neuropharmacology·Nimish Sidhpura, Loren H Parsons
Sep 20, 2012·Drug Testing and Analysis·G C LoewingerJ F Cheer
Jul 2, 2010·British Journal of Pharmacology·Leigh V PanlilioSteven R Goldberg
Apr 23, 2014·British Journal of Pharmacology·Christina J PerryAndrew J Lawrence
Sep 17, 2015·Nature Reviews. Neuroscience·Loren H Parsons, Yasmin L Hurd
Jan 15, 2015·European Journal of Pharmacology·George F Koob
Mar 11, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Zuzana JustinovaSteven R Goldberg
Dec 19, 2014·The International Journal of Neuropsychopharmacology·Claudia ChauvetMarcello Solinas
Mar 21, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Christopher J Fowler
Jul 19, 2011·Brain Research Bulletin·Siamak Shahidi, Parisa Hasanein
Feb 18, 2015·Pharmacology, Biochemistry, and Behavior·Parisa Hasanein, Massoud Teimuri Far

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.